Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Radioactive Bacteria Designed to Treat Metastatic Pancreatic Cancer

By BiotechDaily International staff writers
Posted on 08 May 2013
Scientists have developed a pancreatic cancer therapy that uses Listeria bacteria to selectively infect tumor cells and deliver radioisotopes into them. The investigational treatment was shown to drastically decrease the number of metastases in a mouse model of highly aggressive pancreatic cancer without injuring normal tissue.

The study’s findings were published April 22, 2013, in the online edition of the Proceedings of the National Academy of Sciences of the United States of America (PNAS). “We’re encouraged that we’ve been able to achieve a 90% reduction in metastases in our first round of experiments,” said cosenior author Claudia Gravekamp, PhD, associate professor of microbiology and immunology at Albert Einstein College of Medicine of Yeshiva University (Bronx, NY, USA), who studies new approaches to treating metastatic cancer. “With further improvements, our approach has the potential to start a new era in the treatment of metastatic pancreatic cancer.”

Scientists, a while ago, observed that an attenuated form of Listeria monocytogenes could infect cancer cells, but not normal cells. In a 2009 study, Dr. Gravekamp discovered why—the tumor microenvironment inhibits the body’s immune response, allowing Listeria to survive inside the tumors. By contrast, the weakened bacteria are rapidly eliminated in normal tissues.

Scientists later demonstrated that Listeria could be exploited to convey an anticancer drug to tumor cells in laboratory cultures, but this strategy was never assessed in an animal model. These findings encouraged Dr. Gravekamp to examine Listeria-tumor interactions and how Listeria could be used to attack cancer cells.

The concept of attaching radioisotopes (typically utilized in cancer therapy) to Listeria was suggested by Ekaterina Dadachova, PhD, professor of radiology and of microbiology and immunology at Einstein and the study’s cosenior author. Dr. Dadachova, is a pioneer in developing radioimmunotherapies, i.e., patented treatments in which radioisotopes are attached to antibodies to selectively target cells including cancer cells, microbes or cells infected with HIV. When the antibodies bind to antigens that are unique to the cells being targeted, the radioisotopes emit radiation that selectively kills the cells.

Working together, Drs. Gravekamp and Dadachova coupled the radioactive isotope rhenium to the weakened Listeria bacteria. “We chose rhenium because it emits beta particles, which are very effective in treating cancer,” said Dr. Dadachova. “Also, rhenium has a half-life of 17 hours, so it is cleared from the body relatively quickly, minimizing damage to healthy tissue.”

Mice with metastatic pancreatic cancer were given intra-abdominal injections of the radioactive Listeria once a day for seven days, followed by a seven-day “rest” period and four additional daily injections of the radioactive bacteria. After 21 days, the scientists counted the number of metastases in the mice. The treatment had decreases the metastases by 90% compared with untreated controls. Furthermore, the radioactive Listeria had concentrated in metastases and to a lesser extent in primary tumors but not in healthy tissues, and the treated mice did not appear to suffer any ill effects.

The treatment may have the possibilities for treating an even higher percentage of metastases. “We stopped the experiment at 21 days because that’s when the control mice start dying,” said Dr. Dadachova. “Our next step is to assess whether the treatment affects the animals' survival.”

“At this point, we can say that we have a therapy that is very effective for reducing metastasis in mice,” Dr. Gravekamp noted. “Our goal is to clear 100% of the metastases, because every cancer cell that stays behind can potentially form new tumors.”

The researchers expect the treatment could be enhanced by using higher doses of radiation, modifying the treatment schedule, or by adding more anticancer agents onto the bacteria. Einstein has filed a patent application related to this research that is currently available for licensing to partners interested in further developing and commercializing this technology.

Related Links:
Albert Einstein College of Medicine of Yeshiva University


comments powered by Disqus

Channels

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.